Search

The receptor for advanced glycation end products (RAGE) is a key contributor to the immune and inflammatory response in a myriad of diseases. RAGE is a transmembrane pattern recognition receptor with special interest in pulmonary anomalies due to its naturally abundant expression in the lungs. Our previous studies demonstrated a role for RAGE in inflammation following acute exposure to secondhand smoke (SHS). However, chronic inflammatory mechanisms associated with RAGE have yet to be fully elucidated. In this study, we address the impact of long-term SHS exposure on RAGE signaling. RAGE knockout (RKO) and wild type (WT) mice were exposed to SHS five times weekly via a nose-only delivery system (Scireq Scientific, Montreal, Canada) for six months. SHS animals were compared to mice exposed to room air only. Immunoblot and colorimetric high throughput FACE assays (Active Motif) were used to assess phospho-AKT and NF-κB, respectively. A mouse cytokine antibody array (Abcam) was used to screen secreted cytokines in bronchoalveolar lavage fluid (BALF). Phospho-AKT was decreased and NF-κB was elevated in both groups of SHS exposed mice, with RKO+SHS mice demonstrating tempered outcomes for both intermediates compared to WT+SHS exposed mice. BALF contained increased levels of pro-inflammatory cytokines including IFNγ, IL-13, MIP-1γ and Eotaxin1 in exposed groups and diminished secretion was observed in exposed RKO mice. These results validate a role for RAGE in the mediation of chronic pulmonary inflammatory responses and suggest AKT signaling as a viable pathway of RAGE dependent inflammatory responses. Additional characterization of RAGE-mediated pulmonary responses to prolonged exposure will provide valuable insight into cellular mechanisms of lung diseases such as chronic obstructive pulmonary disease. This work was supported by funding from the National Institutes of Health (NIH 1R15-HL152257, PRR and JAA). This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Limb-girdle muscular dystrophy type 2B (LGMD2B) is a devastating autosomal recessive disease for which there are no current FDA-approved treatments. Our previous research shows that short-term recombinant human Galectin-1 (rHsGal-1) treatment is effective in improving muscle repair and decreasing fat deposition in the BLA/J mouse model. Our current objective is to determine the efficacy of a long-term (6-month) weekly treatment with rHsGal-1 in improving disease pathology in BLA/J mice. Mice treated weekly with intraperitoneal injections of 2.7 mg/kg rHsGal-1 show significant improvements in the time it takes to cross a 10 mm wide balance beam in comparison with saline-injected mice. Treated mice also show less decline over time in how often they rear on their hind legs while exploring a new environment, which suggests improved pathology of the psoas and gluteus muscles, which are especially affected in the BLA/J model. Oil Red O staining of the psoas muscles shows decreased lipid deposition in the muscle of rHsGal-1 treated mice. Other histological stains show improved pathology in various affected muscles. We conclude that weekly treatment with rHsGal-1 is a promising therapeutic for individuals with LGMD2B. This research is funded by the Jain Foundation This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Duchenne muscular dystrophy (DMD) is a devastating disease caused by mutations in the dystrophin gene that result in the complete absence of dystrophin protein. We have shown previously that recombinant mouse Galectin-1 treatment improves physiological and histological outcome measures in the mdx mouse model of DMD. Because recombinant human Galectin-1 (rHsGal1) will be used to treat DMD patients, we performed a dose-ranging study and intraperitoneal or intravenous delivery to determine the efficacy of rHsGal1 to improve preclinical outcome measures in mdx mice. Our studies showed that the optimal dose of rHsGal1 delivered intraperitoneally was 20 mg/kg and that this treatment improved muscle strength, sarcolemma stability, and capillary density in skeletal muscle. We next examined the efficacy of intravenous delivery and found that a dose of 2.5 mg/kg rHsGal1 was well tolerated and improved outcome measures in the mdx mouse model. Our studies identified that intravenous doses of rHsGal1 exceeding 2.5 mg/kg resulted in toxicity, indicating that dosing using this delivery mechanism will need to be carefully monitored. Our results support the idea that rHsGal1 treatment can improve outcome measures in the mdx mouse model and support further development as a potential therapeutic agent for DMD. Keywords: Duchenne muscular dystrophy, Galectin-1, protein therapeutic, biologic, vascularization